DE60120366D1 - Arylkondensiete azapolycyclische derivate - Google Patents

Arylkondensiete azapolycyclische derivate

Info

Publication number
DE60120366D1
DE60120366D1 DE60120366T DE60120366T DE60120366D1 DE 60120366 D1 DE60120366 D1 DE 60120366D1 DE 60120366 T DE60120366 T DE 60120366T DE 60120366 T DE60120366 T DE 60120366T DE 60120366 D1 DE60120366 D1 DE 60120366D1
Authority
DE
Germany
Prior art keywords
azapolyclic
derivatives
aryl condensing
condensing
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120366T
Other languages
English (en)
Other versions
DE60120366T2 (de
Inventor
P R P Brooks
J W Coe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60120366D1 publication Critical patent/DE60120366D1/de
Publication of DE60120366T2 publication Critical patent/DE60120366T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60120366T 2000-02-25 2001-02-08 Aryl-kondensierte azopolycyclische Verbindungen Expired - Lifetime DE60120366T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US514002 2000-02-25
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds
PCT/IB2001/000153 WO2001062736A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
DE60120366D1 true DE60120366D1 (de) 2006-07-20
DE60120366T2 DE60120366T2 (de) 2007-07-05

Family

ID=24045406

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60120366T Expired - Lifetime DE60120366T2 (de) 2000-02-25 2001-02-08 Aryl-kondensierte azopolycyclische Verbindungen
DE60140965T Expired - Lifetime DE60140965D1 (de) 2000-02-25 2001-02-08 Arylkondensierte azapolycyclische derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60140965T Expired - Lifetime DE60140965D1 (de) 2000-02-25 2001-02-08 Arylkondensierte azapolycyclische derivate

Country Status (40)

Country Link
US (3) US6605610B1 (de)
EP (2) EP1259489B1 (de)
JP (1) JP2003524002A (de)
KR (1) KR100537976B1 (de)
CN (1) CN1263745C (de)
AP (1) AP1860A (de)
AT (2) ATE328872T1 (de)
AU (2) AU784081B2 (de)
BG (1) BG65891B1 (de)
BR (1) BR0108610A (de)
CA (1) CA2401229C (de)
CR (1) CR6726A (de)
CU (1) CU23148A3 (de)
CY (1) CY1105301T1 (de)
CZ (1) CZ303203B6 (de)
DE (2) DE60120366T2 (de)
DK (2) DK1619192T3 (de)
DZ (1) DZ3328A1 (de)
EA (1) EA005316B1 (de)
EE (1) EE200200475A (de)
ES (2) ES2336800T3 (de)
GE (1) GEP20053454B (de)
HK (1) HK1050894A1 (de)
HR (1) HRP20020700A2 (de)
HU (1) HU229482B1 (de)
IL (2) IL150639A0 (de)
IS (1) IS2293B (de)
MA (1) MA26875A1 (de)
MX (1) MXPA02008311A (de)
NO (1) NO323608B1 (de)
NZ (1) NZ519973A (de)
OA (1) OA12181A (de)
PL (1) PL365163A1 (de)
PT (1) PT1259489E (de)
RS (1) RS51123B (de)
SI (1) SI1259489T1 (de)
SK (1) SK12042002A3 (de)
UA (1) UA74813C2 (de)
WO (1) WO2001062736A1 (de)
ZA (1) ZA200206768B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504482A (en) * 1997-12-31 2003-01-31 Pfizer Prod Inc Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
BR0208992A (pt) * 2001-04-20 2004-04-27 Pfizer Prod Inc Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila
CN1568184A (zh) * 2001-10-31 2005-01-19 辉瑞产品公司 烟碱乙酰胆碱受体激动剂在治疗多动腿综合征中的用途
JP2005510568A (ja) * 2001-11-30 2005-04-21 ファイザー・プロダクツ・インク アリール基が結合したアザポリサイクリック化合物
NZ532435A (en) * 2001-11-30 2005-04-29 Pfizer Prod Inc Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP2174714B1 (de) * 2002-10-22 2013-04-17 EMD Millipore Corporation Vorrichtung mit einer Kompositestruktur zum Probe Vorbereitung
PL377292A1 (pl) * 2002-11-25 2006-01-23 Pfizer Products Inc. Ulepszony sposób wytwarzania 1,3-podstawionych indenów
BRPI0406670A (pt) * 2003-01-15 2005-12-20 Pfizer Prod Inc Processo para a preparação de lactamas policìclicas fundidos com arila
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
DK1638971T3 (da) * 2003-06-04 2008-10-27 Pfizer Prod Inc Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
ES2368916T3 (es) 2003-10-14 2011-11-23 Xenoport, Inc. Forma cristalina de un análogo del ácido gamma-aminobutírico.
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
KR20070098942A (ko) * 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 고순도의 치환된 퀴녹살린의 제조 방법
KR20090007568A (ko) * 2006-04-24 2009-01-19 화이자 프로덕츠 인코포레이티드 약물 전달 장치용 비대칭 막
EP2086977A2 (de) * 2006-11-09 2009-08-12 Pfizer Products Inc. Polymorphe aus nikotin-zwischenprodukten
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
NZ586651A (en) * 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
BRPI1008020A2 (pt) * 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
EP2435080A2 (de) 2009-05-29 2012-04-04 Abbott Laboratories Pharmazeutische zusammensetzungen zur schmerzbehandlung
RU2012102052A (ru) * 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
KR20180101268A (ko) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
US20230116114A1 (en) * 2020-01-03 2023-04-13 Blue Oak Pharmaceuticals, Inc. Compounds and compositions for treating cns disorders
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
NZ504482A (en) * 1997-12-31 2003-01-31 Pfizer Prod Inc Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
EP0955301A3 (de) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-Aza-bicyclo[2.2.1]-heptan Derivate, deren Herstellung und Verwendung aufgrund ihrer Affinität für neuronale nikotinische Acetylcholin Rezeptoren
IL138917A0 (en) 1998-04-29 2001-11-25 Pfizer Prod Inc Aryl fused azapolycyclic compounds
ATE253067T1 (de) * 1999-01-29 2003-11-15 Abbott Lab Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1372692A4 (de) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer Asymmetrische synthese von (s, s, r)-(-)-actinonin und seinen analogen und verwendungen davon
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
EP1259489A1 (de) 2002-11-27
IS6459A (is) 2002-07-05
CR6726A (es) 2003-10-28
ES2336800T3 (es) 2010-04-16
PL365163A1 (en) 2004-12-27
IL150639A0 (en) 2003-02-12
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
AU2005234671A1 (en) 2005-12-15
AU2874801A (en) 2001-09-03
DK1619192T3 (da) 2010-03-29
BR0108610A (pt) 2002-11-19
OA12181A (en) 2006-05-09
ATE328872T1 (de) 2006-06-15
CN1263745C (zh) 2006-07-12
CZ303203B6 (cs) 2012-05-23
RS51123B (sr) 2010-10-31
NO323608B1 (no) 2007-06-18
SK12042002A3 (sk) 2004-02-03
ZA200206768B (en) 2003-09-23
EP1619192B1 (de) 2009-12-30
US6605610B1 (en) 2003-08-12
US7144882B2 (en) 2006-12-05
HRP20020700A2 (en) 2004-12-31
EP1619192A2 (de) 2006-01-25
DE60140965D1 (de) 2010-02-11
HK1050894A1 (en) 2003-07-11
CZ20022778A3 (cs) 2003-09-17
US7205300B2 (en) 2007-04-17
SI1259489T1 (sl) 2006-10-31
DE60120366T2 (de) 2007-07-05
NO20024042D0 (no) 2002-08-23
HU229482B1 (en) 2014-01-28
MXPA02008311A (es) 2002-12-09
CY1105301T1 (el) 2010-03-03
PT1259489E (pt) 2006-08-31
JP2003524002A (ja) 2003-08-12
IS2293B (is) 2007-10-15
EA005316B1 (ru) 2004-12-30
KR100537976B1 (ko) 2005-12-21
EA200200716A1 (ru) 2003-02-27
AU2005234671B2 (en) 2008-04-17
KR20030005209A (ko) 2003-01-17
ES2263640T3 (es) 2006-12-16
MA26875A1 (fr) 2004-12-20
BG106908A (bg) 2003-04-30
BG65891B1 (bg) 2010-04-30
DK1259489T3 (da) 2006-10-09
CN1406227A (zh) 2003-03-26
UA74813C2 (en) 2006-02-15
WO2001062736A1 (en) 2001-08-30
HUP0204580A2 (hu) 2003-04-28
YU59602A (sh) 2005-06-10
CA2401229C (en) 2007-10-02
EE200200475A (et) 2003-12-15
CA2401229A1 (en) 2001-08-30
DZ3328A1 (de) 2001-08-30
EP1259489B1 (de) 2006-06-07
EP1619192A3 (de) 2006-03-22
AU784081B2 (en) 2006-02-02
AP2002002604A0 (en) 2002-09-30
HUP0204580A3 (en) 2005-04-28
ATE453643T1 (de) 2010-01-15
US20030130261A1 (en) 2003-07-10
CU23148A3 (es) 2006-06-29
GEP20053454B (en) 2005-02-25
AP1860A (en) 2008-07-02
IL150639A (en) 2011-10-31
US20030130260A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
DE60120366D1 (de) Arylkondensiete azapolycyclische derivate
DE60009147D1 (de) Admantan derivate
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DE60036053D1 (de) Erythropoietin Derivate
ATE326470T1 (de) Neue aza-indolyl derivate
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DE60105020D1 (de) 6-phenylpyrrolopyrimidindion derivate
DE60212275D1 (de) Wäschtrockner
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
DE69928262D1 (de) Substituierte chinazoline derivate
DE50114491D1 (de) Substituierte C-Cyclohexylmethylamin-Derivative
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
DE69904738D1 (de) 2-phenylpyran-4-one derivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
DE60143905D1 (de) Phtalazinon derivate
DE60215804D1 (de) 4-aminopyrimidine derivate
NO20042214D0 (no) Aryl kondenserte azaplycykliske forbindelser
DK1322590T3 (da) Substituerede 5-amino-1-penten-3-ol-derivater
ATE269316T1 (de) 2-phenylpyran-4-on derivate
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition